Soleno Therapeutics, Inc. — Department of Health and Human Services SBIR Phase I: NHLBI

Description

DESCRIPTION provided by applicant Sickle cell disease SCD is an inherited anemia in which formation of hemoglobin polymer causes destruction of the red blood cells a process called hemolysis SCD is recognized as a significant global public health problem Over of the annual births with SCD occur in resource poor countries and most of the affected children die from preventable causes Thus there exists an urgent need for technologies to screen infants for SCD so that appropriate health care measures can be initiated The aim of this proposal is to develop a robust point of care diagnostic system based upon measurement of breath carbon monoxide CO level CO in exhaled breath is largely derived from the oxygen dependent catabolism of heme during destruction of red blood cells a process accelerated in SCD Capnia has a device CoSenseandquot which is currently cleared by the FDA for End Tidal Carbon Monoxide ETCO monitoring The use of end tidal breath samples allows the measurement of exhaled CO in young children who cannot provide a forced breath sample A recent preliminary study demonstrated that ETCO levels measured by CoSense were fold higher in SCD than the controls Therefore CoSense as a screening tool may be extremely helpful in identifying infants with SCD in resource poor countries where newborn screening is not available In Phase I of the SBIR proposal the current device will be modified to extend its temperature operating range PUBLIC HEALTH RELEVANCE Over babies are born with sickle cell disease every year principally in Africa and India Most of these children die in the first few years of life uness the disease can be diagnosed early In this project we propose to develop a device which measures carbon monoxide concentration in the breath to screen for sickle cell disease during infancy End of Abstract